UTIX Effervescent Granules

Each 4g sachet contains:

Sodium bicarbonate	1760 mg
Tartaric acid	890 mg
Citric acid anhydrous	720 mg
Sodium citrate anhydrous	630 mg

Also contains lime flavour.

Description:
Appearance of powder: White to off white granular powder with odour of lime flavor
Appearance of solution: Clear to slight haze solution with odour of lime flavour

Pharmacodynamics:
Sodium bicarbonate acts as urinary alkaliser by increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining alkali urine, the actual dissolution of uric acid stones may be accomplished.
Sodium Citrate and Citric Acid:
A rise in urinary pH increased the solubility of cysteine in the urine and the ionization of uric acids to more soluble urate ion. By maintaining alkaline urine, the actual dissolution of uric acid stones may be accomplished.
Tartaric acid in combination with bicarbonates acts as the acid component of effervescent granules.

Pharmacokinetics:
Sodium citrate is metabolized to bicarbonates, which increases urinary pH by increasing the excretions of free bicarbonate ions, without producing systemic alkalosis when administered in recommended doses. Sodium bicarbonate is excreted through renal and also via lung by forming CO_2. Sodium citrate, citric acid and absorbed tartaric acid are excreted through urine.

Indications:
Indicated for relieving of discomfort in mild UTI; symptomatic relief of dysuria; to enhance the action of certain antibiotics, especially some sulphonamides; in gout therapy as urinary alkalinisers to prevent crystallization of urates.

Dosage and Administration:
4g to 8g (1 to 2 sachets) dissolved in cold water four times daily for 5 days or as directed by the physician.

Route of administration: Oral administration

Contraindications:
- Renal failure or hypernatremia
- Hexamine mandelate or hexamine hippurate therapy
- Caution is advised in overt and occult cardiac failure
- Concomitant use of urinary alkalinisers and quinolone antibiotics should also be avoided because crystalluria may be more likely to occur in alkaline urine

Precautions/Warnings:
Those on a low sodium diet should take into account of the sodium content (650mg of per sachet) of this product.

Drug Interactions:
Alkalinization of the urine due to the use of UTIX, theoretically, may result in a decreased therapeutic affect to the following medications, chlorpropemide, lithium, salicylates and tetracyclines.
Alternatively, alkalinization of the urine due to the use of UTIX, theoretically, may result in an increased therapeutic effect of the following medications, amphetamines and ephedrine/pseudoepherine.
Antacid: Concurrent use of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid stones and may also cause hypernatremia.
Concurrent use at aluminium-containing antacids with salts can increase aluminium absorption, possibly resulting in acute aluminium toxicity, especially in patients with renal insufficiency.
Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin, or ofloxacin in the urine. Patients should be observed for signs of crystalluria and nephrotocixity.
Laxatives: Concurrent administration of citrates with laxatives may have an additive effect.
Hexamine hippurate/mandelate (inactive) is hydrolysed to formaldehyde (active) in acidic urine. Urinary alkalinisation prevents the formation of formaldehyde and thus reduces the antibacterial effect of hexamine.

Pregnancy:
Effects of this product on pregnant women have not been carried out.
Nursing Mothers:
Caution should be exercised when administered to a nursing mother.

Side Effects/Adverse Reactions:
The tartrate component of UTIX may be incompletely absorbed. Because of this UTIX may exert a mild laxative effect. Prolonged and excessive use may cause a systemic alkolosis and/ or hypernatremia.

Overdosage:
Overdosage may result in metabolic alkalosis. UTIX should be discontinued, appropriate treatment instituted and electrolyte and acid-base determinations should be carried out.

Pack Size:
Effervescent granules, 12x4g sachets or 28x4g sachets per pack.

Storage Conditions:
Storage below 30°C.

Shelf life:
3 years

Manufacturer:
Noripharma Sdn. Bhd. (792633-A)
Lot 5030, Jalan Teratai,
5 ½ Miles off Jalan Meru,
41050 Klang, Selangor

Date of revision: December 2020